ArticleBiomaterials research2022
A drug delivery system constructed by a fusion peptide capturing exosomes targets to titanium implants accurately resulting the enhancement of osseointegration peri-implant.
Article in Biomaterials research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Nano-Engineered Titanium Implants Loaded With Gingival Fibroblasts-Derived Microvesicles Enhance Early Osseointegration And Soft Tissue Attachment In Vivo.Advanced healthcare materials · 2026Article
- Extracellular Vesicles as Orchestrators of Osteoimmunomodulation in Peri-Implantitis: Implications for Bone Regeneration.Clinical implant dentistry and related research · 2026Review
- Cerebrolysin-loaded platelet-rich plasma exosomes: Restoring immune homeostasis via TNF-α/IL-10 modulation and apoptosis targeting for spinal cord injury repair.The journal of spinal cord medicine · 2026Article
- Bioactive Silk Fibroin Hydrogel Harnesses BMSCs-EVs to Modulate Inflammatory Microenvironment in Intervertebral Disc Degeneration.Journal of extracellular vesicles · 2025Article
- Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines.Signal transduction and targeted therapy · 2025Review
- Advancing osteoarthritis therapy with GMOCS hydrogel-loaded BMSCs-exos.Journal of nanobiotechnology · 2024Article
- Bacteria extracellular vesicle as nanopharmaceuticals for versatile biomedical potential.Nano convergence · 2024Review
- Engineering tunable dual peptide hybrid coatings promote osseointegration of implants.Materials today. Bio · 2024Article
- Osseointegration-Related Exosomes for Surface Functionalization of Titanium Implants.Biomaterials research · 2024Review
- Exosome-based engineering strategies for the diagnosis and treatment of oral and maxillofacial diseases.Journal of nanobiotechnology · 2023Review
- Design of chimeric GLP-1A using oligomeric bile acids to utilize transporter-mediated endocytosis for oral delivery.Biomaterials research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundExosomes derived from bone marrow mesenchymal stem cells (BMSC-exos) have been shown triggering osteogenic differentiation and mineralization of MSCs, but exosomes administered via bolus injections are rapidly sequestered and cleared. Therefore, we considered the implant as a new organ of patient's body and expected to find a method to treat implant with BMSC-exos in vivo directly.
methodsA fusion peptide (PEP), as a drug delivery system (DDS) which contained a titanium-binding peptide (TBP) possessing the ability to selectively bind to the titanium surface and another peptide CP05 being able to capture exosomes expertly, is constructed to modify the titanium surface.
resultsBoth in vitro and in vivo experiments prove PEP retains the ability to bind titanium and exosome simultaneously, and the DDS gain the ability to target exosomes to titanium implants surface following enhancing osseointegration post-implantation. Moreover, the DDS constructed by exosomes of diverse origins shows the similar combination rate and efficiency of therapy.
conclusionThis drug delivery system demonstrates the concept that EXO-PEP system can offer an accurate and efficient therapy for treating implants with long-term effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.